Paolo Ghia, MD

Articles

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

December 10th 2023

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Treatment Options for Patients with CLL Progressing on Covalent BTK Inhibitors

July 25th 2023

Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.

Molecular Mechanisms of Resistance to Acalabrutinib in CLL

July 25th 2023

Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.

Clinical Considerations for BTK Inhibitor Treatment Selection

July 21st 2023

Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.

Comparing BTK Inhibitors: Key Findings from Head-to-Head Trials

July 21st 2023

An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.

Covalent BTK Inhibitors in Relapsed/Refractory CLL

July 14th 2023

Subject-matter experts review treatment options for patients with relapsed/refractory CLL.

Mechanism and Frontline Use of BTK Inhibitors in CLL

July 14th 2023

Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).

Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib

June 28th 2023

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Dr. Ghia on the Results From the 2-Year Follow-Up of the CAPTIVATE Study in CLL

December 13th 2021

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. Ghia on the Clinical Implications of the CAPTIVATE Trial in CLL

July 13th 2021

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ghia on the Rationale for the CAPTIVATE Trial in CLL

June 29th 2021

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Dr. Ghia on Lack of OS Advantage With Acalabrutinib Per ASCEND Trial in CLL

August 10th 2020

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

Dr. Ghia on the Shift From Chemotherapy to Novel Agents in CLL

July 15th 2020

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia.

Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL

July 9th 2020

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Ghia on Updated ASCEND Trial Results in Relapsed/Refractory CLL

July 6th 2020

Paolo Ghia, MD, PhD, discusses updated results from the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Ghia on ASCEND Trial Results for Previously Treated CLL

September 10th 2019

Paolo Ghia, MD, discusses the efficacy results of the ASCEND trial, which examined the use of acalabrutinib monotherapy in patients with previously treated chronic lymphocytic leukemia.